Prof Mohamad Mohty speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the promising CAR T-cell therapy for acute leukaemia patients.
He explains that a substantial proportion of acute lymphocytic leukaemia and non-Hodgkin lymphoma patients are cured after this treatment.
Prof Mohty believes that the major issue currently faced is a lack of 'persistence' of these cells, but there are many different possibilities that can improve this.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.